Related Experiment Video

Updated: Feb 26, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.0K

Ototoxicity monitoring in children treated with platinum chemotherapy

Beth Brooks1, Kristin Knight2

  • 1a Registered Audiologist , British Columbia's Children's Hospital , Vancouver , BC , Canada and.

International Journal of Audiology
|July 25, 2017
PubMed

Insights

Platinum-based chemotherapy can cause hearing loss in children with cancer. Early detection of this ototoxicity is crucial for effective hearing rehabilitation and improving survivors' quality of life.

Area of Science:

  • Pediatric Oncology
  • Ototoxicity Research
  • Audiology

Background:

  • Platinum-based chemotherapy agents, like cisplatin, are vital in treating childhood cancers.
  • Otototoxicity is a significant dose-limiting toxicity associated with platinum agents, leading to hearing impairment.
  • Pediatric cancer survivors face long-term challenges due to treatment-related hearing loss.

Purpose of the Study:

  • To comprehensively review platinum-induced ototoxicity in pediatric cancer patients.
  • To discuss current strategies for monitoring hearing in young children undergoing cancer treatment.
  • To outline guidelines for the long-term follow-up of hearing in childhood cancer survivors.

Main Methods:

  • A narrative literature review was conducted.
  • Published evidence on ototoxicity prevalence, mechanisms, clinical presentation, risk factors, and implications was synthesized.
  • Current monitoring techniques and follow-up protocols were evaluated.

Main Results:

  • Children receiving cisplatin chemotherapy face a high risk of developing ototoxicity and subsequent hearing loss.
  • Accurate and timely identification of ototoxicity is essential for treatment adjustments and hearing rehabilitation.
  • Specific audiological testing frequencies and sequences may be required due to the nature of platinum-induced hearing loss.

Conclusions:

  • Platinum-induced ototoxicity poses a significant threat to hearing in pediatric cancer patients.
  • Effective hearing monitoring during and after cancer treatment is critical.
  • Addressing hearing loss is vital for the communication, learning, and overall quality of life of childhood cancer survivors.
Abstract

Keywords:
Hearing losscarboplatinchildrencisplatinototoxicity

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.5K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
741
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
434
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
376
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
300
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
332
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
283